Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Study of COR388 HCl in Alzheimer's Disease
2019-000370-27Phase 2Unknown
- Sponsor
- IRulya Therapeutics
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atuzaginstat in Alzheimer's disease (AD) (3 arms), sponsored by IRulya Therapeutics. Primary endpoint: Co-primary efficacy endpoints. Status: unknown.
02
Drugs
atuzaginstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2019-000370-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000370-27.